This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol [0.03%]
代谢功能紊乱相关性脂肪肝的MRI影像特征：多参数MRI检查的潜力
Anja M Fischer,Nazim Lechea,Harvey O Coxson
Anja M Fischer
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with a broad spectrum defined by liver biopsy. This gold standard method evaluates three features: steatosis, activity (ballooning and lobular inflamm...
Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives [0.03%]
肝癌免疫微环境的异质性：单细胞和空间视角的新进展
Caiyi Cherry Li,Meng Liu,Hsin-Pei Lee et al.
Caiyi Cherry Li et al.
Primary liver cancer is a solid malignancy with a high mortality rate. The success of immunotherapy has shown great promise in improving patient care and highlights a crucial need to understand the complexity of the liver tumor immune micro...
Oluwashanu Balogun,Kari Nejak-Bowen
Oluwashanu Balogun
Hepatic porphyrias are a group of metabolic disorders that are characterized by overproduction and accumulation of porphyrin precursors in the liver. These porphyrins cause neurologic symptoms as well as cutaneous photosensitivity, and in s...
Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment [0.03%]
抗生素和抗真菌药物的肝毒性及其在肝功能障碍中的安全使用
J Ma,E S Björnsson,N Chalasani
J Ma
Idiosyncratic drug-induced liver injury (DILI) is a rare and unpredictable form of hepatotoxicity. While its clinical course is usually benign, cases leading to liver transplantation or death can occur. Based on modern prospective registrie...
Statins in Chronic Liver Disease: Review of the Literature and Future Role [0.03%]
他汀类药物在慢性肝病中的应用：文献回顾及未来展望
Nguyen Pham,Jihane N Benhammou
Nguyen Pham
Chronic liver disease (CLD) is a major contributor to global mortality, morbidity, and healthcare burden. Progress in pharmacotherapeutic for CLD management is lagging given its impact on the global population. While statins are indicated f...
Steven L Flamm,Alessandra Mangia
Steven L Flamm
Although therapy with direct-acting antiviral (DAA) agents achieves high hepatitis C virus (HCV) cure rates and is forgiving of missed doses, certain patient populations, such as people who inject drugs (PWID), are often denied therapy beca...
Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma [0.03%]
紧密连接蛋白作为治疗肝纤维化和肝细胞癌的治疗靶点
Antonio Saviano,Natascha Roehlen,Thomas F Baumert
Antonio Saviano
In the last decade tight junction proteins exposed at the surface of liver or cancer cells have been uncovered as mediators of liver disease biology: Claudin-1 and Occludin are host factors for hepatitis C virus entry and Claudin-1 has been...
Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease? [0.03%]
一般人群和肝病患者的安全饮酒量限度是多少？
Manuel Romero-Gómez,Juan Pablo Arab,Claudia P Oliveira et al.
Manuel Romero-Gómez et al.
Excessive alcohol consumption represents an important burden for health systems worldwide and is a major cause of liver- and cancer-related deaths. Alcohol consumption is mostly assessed by self-report that often underestimates the amount o...
Naoto Fujiwara,Genki Kimura,Hayato Nakagawa
Naoto Fujiwara
Spatial transcriptomics, leveraging sequencing- and imaging-based techniques, has emerged as a groundbreaking technology for mapping gene expression within the complex architectures of tissues. This approach provides an in-depth understandi...
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice [0.03%]
非酒精性脂肪肝病的新命名：代谢异常相关脂肪性肝病的临床实践含义及与代谢异常和饮酒相关的肝脏疾病的影响
Clémence M Canivet,Jérôme Boursier,Rohit Loomba
Clémence M Canivet
In June 2023, under the patronage of the American Association for Study of Liver Disease, the European Association for Study of the Liver, and the Asociación Latinoamericana para el Estudio del Hígado with the involvement of 236 participa...